System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Falk Roeder is an expert in Radiotherapy at Salzburger Landeskliniken (Austria). Falk Roeder has authored 188 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 1 of them ongoing. SLR score: 600 (community average: 125). How the SLR is computed.

LeadR Profile

Falk Roeder Salzburger Landeskliniken Austria
600 ScienceLeadR Reputation 600

Unlock

Register Login
Network Map

Radiotherapy

Subspecialties: Oncology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Paracelsus Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 188

Citations

Citations: 3 221 1st author: 40 Last author: 29 Unique author: 6

Main journals

Radiother Oncol 38
Int J Radiat Oncol Biol Phys 26
Radiat Oncol 21
Strahlenther Onkol 16
BMC Cancer 12

Best Journals

Lancet Oncol 2
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Durvalumab Plus High-Dose Radiation in NSCLC III: Long-Term Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).
PMID 42882867 — registries, lung, neoplasms, carcinoma, non-small-cell lung, maintenance, lung neoplasms, chemoradiotherapy, therapeutics		Cancers (Basel)20260
Expanding the ESMO-MCBS: integrating organ preservation into clinical benefit assessment in rectal cancer.
PMID 42828123 — organ preservation, neoplasms, rectal neoplasms		ESMO Gastrointest Oncol20260
The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis.
PMID 42794869 — radiotherapy, melanoma, multiple chronic conditions, radiotherapy, adjuvant, immunotherapy, therapeutics		Cancers (Basel)20260
FAPI PET-guided tumor volume delineation for radiotherapy planning: A comprehensive review across solid tumors.
PMID 42457474 — radiotherapy, neoplasms, nuclear medicine, fibroblasts		Semin Nucl Med20260
Dosimetric robustness of urethra sparing in ultrahypofractionated prostate SBRT using catheter-based motion tracking.
PMID 42171761 — radiotherapy, prostate, urethra, therapeutics, movement, catheters		Strahlenther Onkol20260

Clinical Studies 11

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 6
Phase 1/Phase 2 3
Phase 2 2

By status:

Recruiting 5
Completed 4
Unknown 2

By type:

Interventional 7
Observational 4

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 3
multicentric5to9 1
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase II double blind randomised placebo controlled trial to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories versus placebo for amelioration of acute radiation proctitis symptoms
2024-519359-27-00 — suppositories, prostate, signs and symptoms, aged, proctitis, therapeutics, budesonide, carcinoma, male		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS